2019
Anti-edema and antioxidant combination therapy for ischemic stroke via glyburide-loaded betulinic acid nanoparticles
Deng G, Ma C, Zhao H, Zhang S, Liu J, Liu F, Chen Z, Chen AT, Yang X, Avery J, Zou P, Du F, Lim KP, Holden D, Li S, Carson RE, Huang Y, Chen Q, Kimberly WT, Simard JM, Sheth KN, Zhou J. Anti-edema and antioxidant combination therapy for ischemic stroke via glyburide-loaded betulinic acid nanoparticles. Theranostics 2019, 9: 6991-7002. PMID: 31660082, PMCID: PMC6815966, DOI: 10.7150/thno.35791.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntioxidantsBetulinic AcidBrain EdemaDrug Delivery SystemsDrug Therapy, CombinationDrugs, Chinese HerbalEucommiaceaeGlyburideHumansMaleMiceMice, Inbred C57BLNanoparticlesPentacyclic TriterpenesPositron Emission Tomography Computed TomographyRatsRats, Sprague-DawleyStrokeTriterpenesConceptsBA nanoparticlesFunctional nanomaterialsMultifunctional nanoparticlesAcid nanoparticlesNanoparticlesSingle-agent pharmacotherapyNanomaterialsDrug deliveryCombination therapyComplementary targetTherapeutic benefitPositron emission tomography-computed tomographyEmission tomography-computed tomographyTomography-computed tomographyIschemia-induced infarctionIschemic brainIschemic strokeStroke treatmentBrain penetrabilityBetulinic acidClinical managementEffective pharmacotherapyIntravenous administrationEffective treatmentMost therapeutics
2017
A multi species evaluation of the radiation dosimetry of [11C]erlotinib, the radiolabeled analog of a clinically utilized tyrosine kinase inhibitor
Petrulli JR, Hansen SB, Abourbeh G, Yaqub M, Bahce I, Holden D, Huang Y, Nabulsi NB, Contessa JN, Mishani E, Lammertsma AA, Morris ED. A multi species evaluation of the radiation dosimetry of [11C]erlotinib, the radiolabeled analog of a clinically utilized tyrosine kinase inhibitor. Nuclear Medicine And Biology 2017, 47: 56-61. PMID: 28126682, PMCID: PMC5360653, DOI: 10.1016/j.nucmedbio.2016.12.009.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCarcinoma, Non-Small-Cell LungErlotinib HydrochlorideFemaleHumansIsotope LabelingLung NeoplasmsMacaca mulattaMicePositron Emission Tomography Computed TomographyProtein Kinase InhibitorsProtein-Tyrosine KinasesRadiometrySwineTissue DistributionConceptsTyrosine kinase inhibitorsTime-activity curvesEquivalent doseNon-small cell lung cancer patientsStage IIIA NSCLC patientsEpidermal growth factor receptor (EGFR) mutationsCell lung cancer patientsCritical organsKinase inhibitorsIIIA NSCLC patientsLung cancer patientsHighest equivalent doseTime-integrated activity coefficientsWhole bodyMean equivalent dosesRhesus macaque monkeysNSCLC patientsDosimetry profileCancer patientsGallbladder wallReceptor mutationsMacaque monkeysIdentifiable organsInjected activityEffective dose